



NRG-HN009: Randomized Phase II/III Trial of Radiation with Cisplatin at 100 mg/m² Every Three Weeks Versus Radiation with Weekly Cisplatin at 40 mg/m² for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NRG-HN010: RA Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

[Click here to Listen](#)

Episode Description: The NRG Oncology Podcast co-hosts interview NRG-HN009 PI Dr. Paul Harari on the recently reported initial results of NRG-HN009 at the 2026 Multidisciplinary Head and Neck Cancer Symposium. Additionally, this episode discusses NRG-HN010 for HER2-expressing salivary gland cancer with Study PI, Dr. Alan Ho.



All episodes of The NRG Oncology Podcast can be found on Spotify, Apple Music, YouTube, & Amazon or you can stream them directly from our website at

www.NRGOncology.org/Podcast